Stocktoria
BriaCell Therapeutics Corp. BCTXL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
BriaCell Therapeutics Corp. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $21.3M | $27.2M | $15.3M | $8.0M | $2.0M |
| Operating income | -$27.2M | -$33.3M | -$23.3M | -$15.3M | -$7.0M |
| Interest expense | — | — | — | $979 | $78,554 |
| Net income | -$26.3M | -$4.8M | -$20.3M | -$26.8M | -$13.8M |
| EPS (diluted) | $-62.19 | $-43.68 | $-1.30 | $-1.73 | — |
| Operating cash flow | -$28.2M | -$24.1M | -$23.7M | -$12.5M | -$7.8M |
| Free cash flow | — | -$24.6M | — | — | — |
| Cash & equivalents | $10.5M | $862,089 | $21.3M | $41.0M | $57.3M |
| Total assets | $21.6M | $5.9M | $27.2M | $42.6M | $58.0M |
| Shareholders' equity | $17.3M | -$2.7M | -$3.8M | $10.3M | $27.7M |
Source: SEC EDGAR filings · CIK 0001610820 · as of 2025-07-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.